Evidence map›Paper›PMID 39078836›Full record

ArticlePloS one2024

COVID-19 and influenza vaccine-hesitancy subgroups.

Karl O Mäki, Linda C Karlsson, Johanna K Kaakinen, Philipp Schmid, Stephan Lewandowsky, Jan Antfolk, Anna Soveri

Abstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Editorial: Dormant Cancer Cells, Cancer Progression, and Post-Acute Sequelae of COVID-19 and Influenza.Medical science monitor : international medical journal of experimental and clinical research · 2025
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Karl O MäkiDepartment of Psychology and Speech-Language Pathology, University of Turku, Turku, Finland.ORCID 0000-0003-4643-9724
Linda C KarlssonDepartment of Clinical Medicine, University of Turku, Turku, Finland.
Johanna K KaakinenDepartment of Psychology and Speech-Language Pathology, University of Turku, Turku, Finland.
Philipp SchmidCentre for Language Studies, Radboud University Nijmegen, Nijmegen, The Netherlands.ORCID 0000-0003-2966-0806
Stephan LewandowskySchool of Psychological Science, University of Bristol, Bristol, United Kingdom.ORCID 0000-0003-1655-2013
Jan AntfolkDepartment of Psychology, Åbo Akademi University, Turku, Finland.
Anna SoveriDepartment of Clinical Medicine, University of Turku, Turku, Finland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Health communicators are faced with the challenge that people can hesitate vaccines for different reasons. Our aim was to identify and describe the qualities of distinct COVID-19 and influenza vaccine-hesitancy subgroups to facilitate the development of tailored vaccine-hesitancy communication. In two studies, we used agglomerative hierarchical cluster analysis to identify COVID-19 (N = 554) and influenza (N = 539) vaccine-hesitancy subgroups in the general population based on nine vaccine hesitancy-related variables (intent to get vaccinated, perceived vaccine safety, perceived vaccine efficacy, perceived disease threat, perceived vaccination responsibility, perceived vaccination convenience, distrust in authorities, conspiracy mentality, and reliance on anecdotal testimonies). We identified and described six distinct COVID-19 vaccine-hesitancy subgroups (the Vaccination Positive, the Ambivalent, the Fearing Skeptic, the Unconvinced, the Constrained Skeptic, and the Vaccination Opponent), and three influenza vaccine-hesitancy subgroups (the Vaccination Positive, the Complacent, and the Vaccination Opponent), with different levels of hesitancy. We discuss the implications of the results for health communicators. Our results shed light on the (dis)similarities between people who hesitate COVID-19 and influenza vaccines and suggest that there is greater variety in hesitancy concerning COVID-19 vaccinations than influenza vaccinations. These findings can be used to design and test tailored vaccination messages.

Indexed as

COVID-19COVID-19 VaccinesInfluenza, HumanInfluenza VaccinesVaccination HesitancyAdolescentAdultAgedFemaleHumansMaleMiddle AgedSARS-CoV-2Surveys and QuestionnairesVaccinationYoung AdultCOVID-19 VaccinesInfluenza Vaccines

Identifiers

PMID39078836
PMCPMC11288446

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.